Iranian biosimilar company CinnaGen obtained GMP certification from EMA

| By | CinnaGen, EMA, GMP certificate
1
2093

The Iranian biosimilar company CinnaGen has achieved a notable first for the Middle East and North Africa (MENA) region.

It has obtained good manufacturing practice (GMP) certification from the European Medicines Agency (EMA), becoming the first full-cycle biologic plant to be approved in the region.

This milestone is a major step forward in CinnaGen’s development of biosimilars for high regulated markets.

With eight manufacturing plants in Iran and Turkey, CinnaGen Pharmaceutical Group is the biggest biotech enterprise in the MENA region. The group employs more than 2,500 people and is aiming to become one of the top 10 biosimilar players in the world.

Its compound annual growth rate, exceeding 58% over the past three years, makes CinnaGen one of the fastest-growing biopharmaceutical companies in region. It is responsible for more than 55% of Iranian pharmaceutical exports and has launched multiple technology transfer projects with its partners across the globe. Also, CinnGen’s leading biosimilar, CinnoVex, has successful presence in Russian market for more than 6 years, CinnaGen is initiating clinical trials to introduce other biosimilars to Russian pharmaceutical market.

SOURCE: CinnaGen
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.